HTR1A and schizophrenia: A significant improvement in schizophrenia therapy came in the early 2000s with the use of aripiprazole acting as a dopamine D2-like partial agonist with partial agonistic properties on serotonergic 5-HT1A and 5-HT2A receptors (Buckley, 2003; Kiss et al., 2010; Johnson et al., 2011).